Hypoxia has also been studied in the context of IBD, and several studies showed that hypoxia inducible factor 1 subunit alpha (HIF-1α) inhibitors improve intestinal barrier function when administered orally [129] or intraperitoneally [130]. This evidence concerns the gene HIF1A and inflammatory bowel disease.